Targeting the cholinergic anti‐inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study
Authors' conclusion
Galantamine use was associated with a lower risk of T2DM in early-onset AD patients, potentially due to enhanced anti-inflammatory effects through both AChE inhibition and direct α7nAChR agonism. Memantine also demonstrated a protective effect. These findings suggest potential new applications for existing AD medications in T2DM prevention, particularly in early-onset AD patients. Further research, including randomized controlled trials with diverse populations, is needed to confirm these results and the underlying mechanisms.
Study context
- Population
- Early- and late-onset Alzheimer's disease patients, Veterans Health Administration
- Participants
- 40,065 participants
- Exposure
- Galantamine vs other Alzheimer's disease (AD) medications
- Outcome
- T2D risk
Methodological detailspropensity score matching, Veterans Health Administration data
- Propensity score matching
- Veterans Health Administration data
Main finding
As reported in the abstract
Galantamine use, early-onset AD: HR
0.80
95% CI 0.66–0.98
Memantine, early-onset AD: HR
0.82
95% CI 0.69–1
Observational data: associations, not effects.
Further findings
T2D risk, late-onset AD
- Neither galantamine nor memantine influenced T2D risk in late-onset AD
T2D risk, other AD medications
- Other AD medications showed no association with T2D risk
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →